Improving inpatient medication management in hospitalized Parkinson’s patients
Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial
Objective: To evaluating the effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial Background:…Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort
Objective: To examine change in clinical characteristics in LRRK2 G2019S carriers with Parkinson’s disease (PD) and without PD (non-manifest carriers) enrolled in Virtual Assessment of…Longitudinal brain volume decline in PD with RBD and olfactory dysfunction
Objective: To elucidate longitudinal brain atrophies in PD with or without RBD and anosmia at baseline. Background: REM sleep behavior disorder (RBD) and olfactory dysfunction…Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson’s Disease and Movement Disorders Clinic
Objective: To evaluate the impact of pharmacist participation in Parkinson’s disease and movement disorders clinic on the number of drug-related problems (DRPs), clinical outcomes, and…monogenic parkinson´s disease in a chilean cohort
Objective: To describe the minimum prevalence and distribution of monogenic forms of PD in a chilean cohort Background: About 3–5% of Parkinson’s disease (PD) patients…Analysis of subthalamic-nuclei deep brain stimulation using radiomic feature-manifestations: a quantitative approach
Objective: To estimate STN by IPGs induced with DBS effects for Parkinson's by ‘radiomic-features(RF)’/symptoms-manifestations attained as of pre-opMRI, study possibility of ‘RF’ of amygdala-nucleus’ plus…Can a global measure of cognition be used to inform balance interventions in Parkinson’s disease?
Objective: To examine the relationship between domains of cognition, using the Montreal Cognitive Assessment (MoCA), and domains of balance, using the Mini Balance Evaluation Systems…Multimodal neuroimaging of Parkinson’s disease with diffusion tensor imaging (DTI) and dopamine transporter (DAT) positron emission tomography
Objective: The main aims of this study were to characterize brain microstructure alterations in a cross-sectional cohort of Parkinson’s disease (PD) with DTI and assess…
- « Previous Page
- 1
- …
- 167
- 168
- 169
- 170
- 171
- …
- 338
- Next Page »